Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet-activating factor antagonists in experimental shock.

G Muacevic1, H O Heuer

  • 1Department of Pharmacology, Boehringer Ingelheim KG, Ingelheim/Rhein, Fed. Rep. of Germany.

Arzneimittel-Forschung
|August 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative effects of a glucocorticosteroid, theophylline and the peptido-leukotriene-antagonist CGP 45715A on antigen-induced early and late phase airway response and inflammatory cell influx in sensitised guinea pigs.

European journal of pharmacology·1999
Same author

Characterisation of a novel airway late phase model in the sensitized guinea pig which uses silica and Bordetella pertussis as adjuvant for sensitization.

European journal of pharmacology·1996
Same author

Pharmacological characterisation of a new model of antigen-induced pulmonary late-phase reaction in the conscious guinea pig which uses additional polymyxin B inhalation.

Journal of lipid mediators and cell signalling·1996
Same author

Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs.

Japanese journal of pharmacology·1996
Same author

Dissociation of airway responsiveness and bronchoalveolar lavage (BAL) cell composition in sensitized guinea-pigs after daily inhalation of ovalbumin.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·1994
Same author

Current status of PAF antagonists.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·1992
Same journal

Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

Arzneimittel-Forschung·2013
Same journal

Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

Arzneimittel-Forschung·2013
Same journal

Leave-one-out procedure in the validation of elimination rate constant analysis.

Arzneimittel-Forschung·2012
Same journal

Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

Arzneimittel-Forschung·2012
Same journal

Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

Arzneimittel-Forschung·2012
Same journal

Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

Arzneimittel-Forschung·2012
See all related articles

Platelet-activating factor (PAF) causes significant physiological changes in rats, mimicking endotoxin shock. PAF antagonists effectively reversed these effects, highlighting their therapeutic potential.

Area of Science:

  • Pharmacology
  • Physiology
  • Toxicology

Background:

  • Platelet-activating factor (PAF) is a potent mediator implicated in various physiological responses.
  • Endotoxin shock involves complex pathophysiological mechanisms, including hemodynamic and metabolic alterations.

Purpose of the Study:

  • To investigate the physiological effects of PAF in rats.
  • To evaluate the efficacy of selective hetrazepinoic PAF antagonists in counteracting PAF-induced changes and mimicking endotoxin shock.
  • To clarify the role of PAF in endotoxin shock models.

Main Methods:

  • Administration of Platelet-activating factor (PAF) intravenously to rats at specific dosages.
  • Induction of hypotension using PAF infusions or intravenous injection of E. coli endotoxin.

Related Experiment Videos

  • Treatment with selective hetrazepinoic PAF antagonists: apafant (WEB 2086), bepafant (WEB 2170), and STY 2108, both pre- and post-treatment.
  • Monitoring of hematological parameters, ECG, acid-base balance, and blood pressure.

    • Main Results:

    • Intravenous PAF induced hyperkalemia, altered hematological parameters, ECG changes, and acid-base imbalance in rats.
    • PAF administration and E. coli endotoxin caused a significant drop in blood pressure.
    • Pre- and post-treatment with apafant, bepafant, and STY 2108 effectively antagonized the observed PAF-induced and endotoxin-induced effects.

    Conclusions:

    • Platelet-activating factor (PAF) can replicate key features of endotoxin shock in a rat model.
    • Selective hetrazepinoic PAF antagonists demonstrate significant efficacy in reversing PAF-mediated physiological disturbances.
    • These findings underscore the utility of hetrazepines in elucidating the role of PAF in shock conditions.